P/B
7,6
Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
$648.7B
Market Cap • 9/22/2026
1887
(139 years)
Founded
1944
(82 years ago)
IPO
NYSE
Listing Exchange
United States
Country
S&P500 Participant
Index Composite • 2026
Valuation
P/S
6,6
P/EBITDA
19,1
P/OCF
23,5
P/FCF
29,2
P/E
31,2
BVPS
34,8
EPS
8,6
Market Cap
Market Cap
648,7B
EV
677B
EV/Revenue
6,9
EV/EBITDA
20
EV/EBIT
25,9
Payout
Dividend Per Share
5,2
Dividend Yield
1,9%
Buyback Yield
0,6%
Total Yield
2,5%
Dividend Yield 5Y
2,6%
Payout
60%
Retained Earnings
171,7B
Profitability
Gross Margin
67,9%
EBITDA Margin
34,6%
EBIT Margin
26,7%
Net Margin
21,5%
D&A/EBITDA
0%
R&D/Revenue
15,5%
Capex/Revenue
5,5%
Capex/D&A
69,2%
Capex/OCF
19,4%
SBC/OCF
5,1%
% PPE
11,7%
% Goodwill
24,1%
ROE
25,7%
ROIC
14,4%
Growth
CAGR Revenue 5Y
1,9%
CAGR Op. Income 5Y
2,8%
CAGR Net Income 5Y
3,4%
CAGR EPS 5Y
5,4%
CAGR OCF 5Y
1,1%
Leverage
N.D./EBITDA
0,8
Debt/Equity
0%
Current Ratio
1,1
Quick Ratio
0,7
Interest Coverage
2582,9%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!